Amgen's Aimovig (erenumab-aooe) Receives FDA's Approval for Prevention of Migraine in Adults
Shots:
- The approval is based on P-IIIb LIBERTY (NCT03096834) study results assessing Aimovig (140mg) vs PBO for duration of 12 weeks
- The study resulted in 50% reduction of monthly migraine days sustained up to 15 months with the use of acute migraine drugs
- Aimovig (erenumab-aooe) is a novel drug used for targeting Calcitonin Gene-Related Peptide Receptor (CGRP-R)- with its awaited EMA approval
Ref: Amgen | Image: Axios
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com